Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1261-1269

  Montagner, Isabella Monia ^a   Banzato, Alessandra ^b   Zuccolotto, Gaia ^b   Renier, Davide ^c   Campisi, Monica ^c   Bassi, PierFrancesco ^d   Zanovello, Paola ^a,b   Rosato, Antonio ^a,b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Fidia Advanced Biopolymers   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bioconjugate; Bladder cancer; Hyaluronan; Paclitaxel

Indexed keywords

BETA TUBULIN; CASPASE; FLUOROCHROME; HERMES ANTIGEN; HYALURONIC ACID; PACLITAXEL;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL DEATH; CONFOCAL MICROSCOPY; DRUG CONJUGATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYSOSOME; MICROTUBULE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

BIOCONJUGATE; BLADDER CANCER; HYALURONAN; PACLITAXEL;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BORON COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; ENDOCYTOSIS; FLUORESCENT DYES; HUMANS; HYALURONIC ACID; LYSOSOMES; MICROSCOPY, CONFOCAL; MICROTUBULES; PACLITAXEL; PROTEIN BINDING; URINARY BLADDER NEOPLASMS;

EID: 84884674473     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.01.005     Document Type: Article

References (34)

1. Borden L.S., Clark P.E., Hall M.C. Bladder cancer. Curr Opin Oncol 2004, 16:257-262.
2. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239-249.
3. Jacobs B.L., Lee C.T., Montie J.E. Bladder cancer in 2010: How far have we come?. CA Cancer J Clin 2010, 60:244-272.
4. Sylvester R.J. Bacillus Calmette-Guerin treatment of non-muscle-invasive bladder cancer. Int J Urol 2011, 18:113-120.
5. Mielke S. Individualized pharmacotherapy with paclitaxel. Curr Opin Oncol 2007, 19:586-589.
6. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004, 4:253-265.
7. Pliarchopoulou K., Laschos K., Pectasides D. Current chemotherapeutic options for the treatment of advanced bladder cancer: A review. Urol Oncol 2010, Sep 13, [Epub ahead of print].
8. Au J.L., Kalns J., Gan Y., et al. Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol 1997, 41:69-74.
9. Crawford E.D. Intravesical therapy for superficial cancer: Need for more options. J Clin Oncol 2002, 20:3185-3186.
10. Weiss R.B., Donehower R.C., Wiernik P.H., et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990, 8:1263-1268.
11. Mugabe C., Hadaschik B.A., Kainthan R.K., et al. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int 2009, 103:978-986.
12. Tsallas A., Jackson J., Burt H. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations. Cancer Chemother Pharmacol 2010, 68:431-444.
13. Rosato A., Banzato A., De Luca G., et al. HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol 2006, 24:207-215.
14. Platt V.M., Szoka F.C. Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008, 5:474-486.
15. Oh E.J., Park K., Kim K.S., et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010, 141:2-12.
16. Nedvetzki S., Gonen E., Assayag N., et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy. Proc Natl Acad Sci U S A 2004, 101:18081-18086.
17. Marhaba R., Zoller M. CD44 in cancer progression: Adhesion, migration, and growth regulation. J Mol Histol 2004, 35:211-231.
18. Misra S., Heldin P., Hascall V.C., et al. HA/CD44 interactions as potential targets for cancer therapy. FEBS J 2011, 278:1429-1443.
19. Maxwell C.A., McCarthy J., Turley E. Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions?. J Cell Sci 2008, 121:925-932.
20. Lipponen P., Aaltoma S., Kosma V.M., et al. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998, 186:157-164.
21. Kong Q.Y., Liu J., Chen X.Y., et al. Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep 2003, 10:51-55.
22. Harada H., Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem 2007, 282:5597-5607.
23. Banzato A., Bobisse S., Rondina M., et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 2008, 14:3598-3606.
24. Quintieri L., Geroni C., Fantin M., et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 2005, 11:1608-1617.
25. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003, 22:9075-9086.
26. Kainthan R.K., Mugabe C., Burt H.M., et al. Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols: Ligand binding properties. Biomacromolecules 2008, 9:886-895.
27. Gaucher G., Marchessault R.H., Leroux J.C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release 2010, 143:2-12.
28. He M., Zhao Z., Yin L., et al. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm 2009, 373:165-173.
29. Pastorino L., Erokhina S., Caneva-Soumetz F., et al. Paclitaxel-containing nano-engineered polymeric capsules towards cancer therapy. J Nanosci Nanotechnol 2009, 9:6753-6759.
30. Bassi P.F., Volpe A., D'Agostino D., et al. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: Results of a phase I study. J Urol 2011, 185:445-449.
31. Luo Y., Ziebell M.R., Prestwich G.D. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000, 1:208-218.
32. Jackson D.G. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol Rev 2009, 230:216-231.
33. Tringali G., Lisi L., Bettella F., et al. The in vitro rabbit whole bladder as a model to investigate the urothelial transport of anticancer agents. The ONCOFID-P paradigm. Pharmacol Res 2008, 58:340-343.
34. Veiseh M., Turley E.A. Hyaluronan metabolism in remodeling extracellular matrix: Probes for imaging and therapy of breast cancer. Integr Biol 2011, 3:304-315.